Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

Yazar
Ruszniewski, Philippe
Yao, James
Herrmann, Ken
Wild, Damian
Virgolini, Irene
Hicks, Rodney J.
Kabasakal, Levent
Kaltsas, Gregory
Lewington, Val
Minozzi, Silvia
Cinquini, Michela
Oberg, Kjell
Oyen, Wim J. G.
O'Toole, Dermot
Pavel, Marianne
Scarpa, Aldo
Taieb, David
Sundin, Anders
Strosberg, Jonathan
Ambrosini, Valentina
Kunikowska, Jolanta
Baudin, Eric
Bodei, Lisa
Bouvier, Catherine
Capdevila, Jaume
Cremonesi, Marta
de Herder, Wouter W.
Dromain, Clarisse
Falconi, Massimo
Fani, Melpomeni
Fanti, Stefano
Üst veri
Tüm öğe kaydını göster
Özet
Nuclear medicine plays an increasingly important role in the management neuroendocrine neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT) have been used in clinical trials and approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).
Bağlantı
http://hdl.handle.net/20.500.12627/172182
https://doi.org/10.1016/j.ejca.2021.01.008
Koleksiyonlar